fb704a
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 14, 2019 (NCT03890302)
Timeline
Indications
Mechanism of action
- Interleukin-6INHIBITOR
IL6 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05018299 | Phase 2 | Sep 30, 2021 | Microbio Co Ltd, Oneness Biotech Co., Ltd. |
| NCT03890302 | Phase 1 | Mar 14, 2019 | Altasciences Company Inc., Microbio Co Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Microbio Co Ltd | For profit | 2 | 1 | 2 | 2019 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2019 |
| Oneness Biotech Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1